<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549042</url>
  </required_header>
  <id_info>
    <org_study_id>NMT 1077-301</org_study_id>
    <nct_id>NCT00549042</nct_id>
  </id_info>
  <brief_title>Study to Test the Effectiveness of Controlled-Release OROS® Hydromorphone HCl Compared to Placebo in Patients With Chronic Low Back Pain</brief_title>
  <official_title>A Phase III, Variable-Dose Titration Followed by a Randomized Double-Blind Study of Controlled-Release OROS® Hydromorphone HCl (NMED-1077) Compared to Placebo in Patients With Chronic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <brief_summary>
    <textblock>
      This study will test an experimental drug called OROS® hydromorphone hydrochloride (HCl)
      (NMED-1077), a once daily opioid analgesic that can relieve pain. A large number of clinical
      studies have been conducted to test this drug. OROS hydromorphone HCl is currently approved
      in both the US and Europe to treat chronic pain.

      The purpose of this study is to compare OROS hydromorphone to placebo to see if it is safe
      and efficacious.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 12 in Mean Pain Intensity</measure>
    <time_frame>Baseline, Week 12 (or final visit)</time_frame>
    <description>Participants rate their pain intensity on a numeric rating scale (NRS), where 0=no pain and 10=worst possible pain, in a daily diary. At Week 12 (or final visit), all measurements during the preceding week are averaged, and the mean change from the mean score at baseline is calculated.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change From Baseline in Mean Pain Intensity Scores Through the Entire 12-week Treatment Phase</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Participants rate their pain on the pain intensity NRS in a daily diary. At each scheduled visit all measurements during the preceding week are collected, and a mean score for each arm is calculated for each visit. Mean scores at baseline and each subsequent visit are plotted on a graph for the entire 12-week treatment period, and an area under the curve calculation is used to determine the mean change from baseline for each arm through the entire 12-week treatment phase.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Mean Patient Global Assessment (PGA) Scores</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Change from Baseline in mean PGA scores collected at each visit (at Baseline, Days 1, 4, 8, 11, and Weeks 2, 3, 4, 6, 8, 10, and 12) using the scale: 1=Excellent, 2=Very Good, 3=Good, 4=Fair, and 5=Poor. The worst possible score is 5.0.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Mean Scores on the Roland-Morris Disability Questionnaire</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Change from baseline in the Roland-Morris Disability Questionnaire (RDQ) score was analyzed for each visit at which the RDQ was administered (Days 1, 8, and Weeks 2, 3, 4, 6, 8, 10, and 12). This is a 24-item inventory with scores ranging from 0 (highest ability) to 24 (lowest ability). Higher scores mean more disability.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Mean Pain Intensity Scores Collected at Scheduled Visits to the Clinic</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Participants rate their pain on the pain intensity NRS at each scheduled visit (Baseline, Days 1, 4, 8, 11, and Weeks 2, 3, 4, 6, 8, 10, and 12), and a mean score is calculated.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>within 12 weeks</time_frame>
    <description>Time to treatment failure is the median number of days from baseline until the earliest day on which the patient's data indicated treatment failure.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">459</enrollment>
  <condition>Chronic Low Back Pain</condition>
  <arm_group>
    <arm_group_label>OROS hydromorphone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OROS hydromorphone</intervention_name>
    <description>hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets</description>
    <arm_group_label>OROS hydromorphone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Patients must have been provided with written consent to participate in the study
             prior to any study procedures, and must understand that they are free to withdraw from
             the study at any time.

          2. Patients who can speak, read, write, and understand English, and must be able to read
             and understand the consent form, complete study-related procedures, and communicate
             with the study staff.

          3. Male and female patients aged 18-75 years, inclusive.

          4. Documented diagnosis of moderate to severe chronic low back pain that must have been
             present

          5. Patients who are classified as non-neuropathic (Class 1 and 2) or neuropathic (Class
             3, 4, 5 and 6) of lower back pain based on the Quebec Task Force Classification of
             Spinal Disorders will be enrolled for this study.

          6. Patients who require daily scheduled opioid analgesics for low back pain for at least
             2 months prior to the screening visit.

          7. Patients with a daily opioid requirement of ≥ 60 mg oral morphine equivalent (≥ 12 mg
             hydromorphone), but ≤ 320 mg morphine (≤ 64 mg hydromorphone) per day within the 2
             months prior to the screening visit.

          8. Patients who, in the Investigator's opinion, are on a stable dose (≥ 2 weeks) of all
             prior analgesics (both opioid and non-opioid) prior to the screening visit.

          9. Female subjects of childbearing potential including those who have had a tubal
             ligation surgery but excluding those who have not experienced a menstrual period for a
             minimum of 2 years, must have a negative serum pregnancy test at screening visit, and
             must consent to utilize a medically acceptable method of contraception throughout the
             entire study period including the washout period and for 1 week after the study is
             completed.

        Exclusion Criteria

          1. Patients with an active diagnosis of fibromyalgia, complex regional pain syndrome
             (including reflex sympathetic dystrophy or causalgia), acute spinal cord compression,
             severe or progressive lower extremity weakness or numbness, bowel or bladder
             dysfunction as a result of cauda equina compression, diabetic amyotrophy, meningitis,
             diskitis, back pain because of secondary infection or tumor, or pain caused by a
             confirmed or suspected neoplasm.

          2. Patients who have undergone a surgical procedure for back pain within 6 months prior
             to the screening visit.

          3. Patients who have had nerve or plexus block, including epidural steroid injections or
             facet blocks, within 1 month prior to the screening visit.

          4. Patients with any other chronic pain condition that, in the investigator's opinion,
             would interfere with the assessment of low back pain (e.g., osteoarthritis, rheumatoid
             arthritis, postherpetic neuralgia, pain associated with diabetic neuropathy, migraine
             headaches requiring opioid therapy).

          5. Patients who are involved in an active workman's compensation or insurance claim or
             disability claim or litigation related to back pain.

          6. Patients who have by history used any illicit drugs of abuse, abused opioids or
             exhibited drug seeking behavior within 5 years prior to the screening visit.

          7. Patients who have abused prescription medication or alcohol within 5 years prior to
             the screening visit.

          8. Patients with a positive alcohol or drugs of abuse test

          9. Women who are pregnant (as indicated by a positive result in a serum pregnancy test
             administered at screening visit), or breast feeding, or planning to breast feed within
             30 days prior to the screening visit.

         10. Patients who have demonstrated allergic reactions or hypersensitivity to opioids.

         11. Patients who have had no bowel movement within three days, or bowel obstruction within
             60 days, prior to the screening visit.

         12. Patients with pre-existing severe narrowing of the gastrointestinal tract secondary
             to:

             prior gastrointestinal surgery (e.g., vagotomy, antrectomy, pyloroplasty,
             gastroplasty, gastrojejunostomy) or gastrointestinal disease resulting in impaired
             gastrointestinal function (e.g., paralytic ileus, gastroparesis, inflammatory bowel
             disease, &quot;short gut&quot; syndrome due to adhesions or decreased transit time, past history
             of peritonitis, cystic fibrosis, chronic intestinal pseudoobstruction, or Meckel
             diverticulum)

         13. Patients who have a major psychiatric condition (e.g., schizophrenia, major
             depression) or who have clinically significant anxiety or depression as defined by a
             Hospital Anxiety and Depression Scale(HADS) score greater than 10.

         14. Patients who have received monoamine oxidase (MAO) inhibitors within 14 days prior to
             the screening visit.

         15. Patients with clinically significant abnormal laboratory results in clinical
             chemistry, hematology or urinalysis including serum glutamic-oxaloacetic
             transaminase/aspartate aminotransferase (AST) or serum glutamic-pyruvic
             transaminase/alanine aminotransferase (ALT) ≥ 3.0 times the upper limit of the
             reference range or a serum creatinine ≥ 2.0 mg/dL at screening.

         16. Patients with a serious or unstable intercurrent illness.

         17. Patients with a history of uncontrolled seizure disorder.

         18. Patients with increased intracranial pressure, mental clouding of unknown etiology,
             coma, or hypotension.

         19. Patients who have severe asthma, severe chronic obstructive pulmonary disease, or any
             other disorder that predisposes the patient to carbon dioxide retention or respiratory
             depression.

         20. Patients who have taken any investigational drug within 30 days prior to the screening
             visit or are currently enrolled in another investigational drug study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 23, 2007</study_first_submitted>
  <study_first_submitted_qc>October 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2007</study_first_posted>
  <results_first_submitted>May 31, 2020</results_first_submitted>
  <results_first_submitted_qc>May 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 17, 2020</results_first_posted>
  <disposition_first_submitted>February 25, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>February 25, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 28, 2019</disposition_first_posted>
  <last_update_submitted>May 31, 2020</last_update_submitted>
  <last_update_submitted_qc>May 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Back Pain</keyword>
  <keyword>Chronic Low Back Pain</keyword>
  <keyword>Chronic Back Pain</keyword>
  <keyword>Pain</keyword>
  <keyword>Chronic Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OROS Hydromorphone</title>
          <description>OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Conversion and Titration Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="459"/>
                <participants group_id="P2" count="0">Per the study design, no patients received placebo during this phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="268"/>
                <participants group_id="P2" count="0">Per the study design, no patients received placebo during this phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Double-blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OROS Hydromorphone</title>
          <description>OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="134"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="268"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.7" spread="10.51"/>
                    <measurement group_id="B2" value="49.5" spread="10.55"/>
                    <measurement group_id="B3" value="48.6" spread="10.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 12 in Mean Pain Intensity</title>
        <description>Participants rate their pain intensity on a numeric rating scale (NRS), where 0=no pain and 10=worst possible pain, in a daily diary. At Week 12 (or final visit), all measurements during the preceding week are averaged, and the mean change from the mean score at baseline is calculated.</description>
        <time_frame>Baseline, Week 12 (or final visit)</time_frame>
        <population>Intent-to-treat population (ITT). One patient (randomized to receive OROS hydromorphone) did not report taking any study medication, and another (randomized to receive placebo) did not have Baseline values for the primary efficacy variable; both were excluded from the ITT population. Therefore, the ITT population had 266 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>OROS Hydromorphone</title>
            <description>OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Mean Pain Intensity</title>
          <description>Participants rate their pain intensity on a numeric rating scale (NRS), where 0=no pain and 10=worst possible pain, in a daily diary. At Week 12 (or final visit), all measurements during the preceding week are averaged, and the mean change from the mean score at baseline is calculated.</description>
          <population>Intent-to-treat population (ITT). One patient (randomized to receive OROS hydromorphone) did not report taking any study medication, and another (randomized to receive placebo) did not have Baseline values for the primary efficacy variable; both were excluded from the ITT population. Therefore, the ITT population had 266 patients.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="-5" upper_limit="5"/>
                    <measurement group_id="O2" value="1.7" lower_limit="-3" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Mean Pain Intensity Scores Through the Entire 12-week Treatment Phase</title>
        <description>Participants rate their pain on the pain intensity NRS in a daily diary. At each scheduled visit all measurements during the preceding week are collected, and a mean score for each arm is calculated for each visit. Mean scores at baseline and each subsequent visit are plotted on a graph for the entire 12-week treatment period, and an area under the curve calculation is used to determine the mean change from baseline for each arm through the entire 12-week treatment phase.</description>
        <time_frame>Baseline through Week 12</time_frame>
        <population>Results are not presented for Other, prespecified outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>OROS Hydromorphone</title>
            <description>OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Pain Intensity Scores Through the Entire 12-week Treatment Phase</title>
          <description>Participants rate their pain on the pain intensity NRS in a daily diary. At each scheduled visit all measurements during the preceding week are collected, and a mean score for each arm is calculated for each visit. Mean scores at baseline and each subsequent visit are plotted on a graph for the entire 12-week treatment period, and an area under the curve calculation is used to determine the mean change from baseline for each arm through the entire 12-week treatment phase.</description>
          <population>Results are not presented for Other, prespecified outcome measures</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Mean Patient Global Assessment (PGA) Scores</title>
        <description>Change from Baseline in mean PGA scores collected at each visit (at Baseline, Days 1, 4, 8, 11, and Weeks 2, 3, 4, 6, 8, 10, and 12) using the scale: 1=Excellent, 2=Very Good, 3=Good, 4=Fair, and 5=Poor. The worst possible score is 5.0.</description>
        <time_frame>Baseline through Week 12</time_frame>
        <population>Results are not presented for Other, prespecified outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>OROS Hydromorphone</title>
            <description>OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Patient Global Assessment (PGA) Scores</title>
          <description>Change from Baseline in mean PGA scores collected at each visit (at Baseline, Days 1, 4, 8, 11, and Weeks 2, 3, 4, 6, 8, 10, and 12) using the scale: 1=Excellent, 2=Very Good, 3=Good, 4=Fair, and 5=Poor. The worst possible score is 5.0.</description>
          <population>Results are not presented for Other, prespecified outcome measures</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Mean Scores on the Roland-Morris Disability Questionnaire</title>
        <description>Change from baseline in the Roland-Morris Disability Questionnaire (RDQ) score was analyzed for each visit at which the RDQ was administered (Days 1, 8, and Weeks 2, 3, 4, 6, 8, 10, and 12). This is a 24-item inventory with scores ranging from 0 (highest ability) to 24 (lowest ability). Higher scores mean more disability.</description>
        <time_frame>Baseline through Week 12</time_frame>
        <population>Results are not presented for Other, prespecified outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>OROS Hydromorphone</title>
            <description>OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Scores on the Roland-Morris Disability Questionnaire</title>
          <description>Change from baseline in the Roland-Morris Disability Questionnaire (RDQ) score was analyzed for each visit at which the RDQ was administered (Days 1, 8, and Weeks 2, 3, 4, 6, 8, 10, and 12). This is a 24-item inventory with scores ranging from 0 (highest ability) to 24 (lowest ability). Higher scores mean more disability.</description>
          <population>Results are not presented for Other, prespecified outcome measures</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Mean Pain Intensity Scores Collected at Scheduled Visits to the Clinic</title>
        <description>Participants rate their pain on the pain intensity NRS at each scheduled visit (Baseline, Days 1, 4, 8, 11, and Weeks 2, 3, 4, 6, 8, 10, and 12), and a mean score is calculated.</description>
        <time_frame>Baseline through Week 12</time_frame>
        <population>Results are not presented for Other, prespecified outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>OROS Hydromorphone</title>
            <description>OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Pain Intensity Scores Collected at Scheduled Visits to the Clinic</title>
          <description>Participants rate their pain on the pain intensity NRS at each scheduled visit (Baseline, Days 1, 4, 8, 11, and Weeks 2, 3, 4, 6, 8, 10, and 12), and a mean score is calculated.</description>
          <population>Results are not presented for Other, prespecified outcome measures</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Treatment Failure</title>
        <description>Time to treatment failure is the median number of days from baseline until the earliest day on which the patient's data indicated treatment failure.</description>
        <time_frame>within 12 weeks</time_frame>
        <population>Results are not presented for Other, prespecified outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>OROS Hydromorphone</title>
            <description>OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure</title>
          <description>Time to treatment failure is the median number of days from baseline until the earliest day on which the patient's data indicated treatment failure.</description>
          <population>Results are not presented for Other, prespecified outcome measures</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety population includes all patients who were enrolled and who took at least one dose of study drug (N=447). Adverse event displays include data from the safety population. The number of subjects who entered the Conversion and Titration phase was 459.</desc>
      <group_list>
        <group group_id="E1">
          <title>Conversion and Titration Phase</title>
          <description>OROS hydromorphone 12, 16, 24, 32, 40, 48, or 64 m</description>
        </group>
        <group group_id="E2">
          <title>OROS Hydromorphone</title>
          <description>OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="447"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="447"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Meningitis herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="447"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="447"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosi</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="447"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="447"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="447"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="447"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Possible kidney stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="447"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="247" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>URT infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alfredo Bozzini, MD</name_or_title>
      <organization>Covidien</organization>
      <phone>314-654-2000</phone>
      <email>Alfredo.Bozzini@covidien.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

